These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 5687020)

  • 1. Delayed hypersensitivity in breast cancer.
    Roberts MM; Williams WJ
    Br J Surg; 1968 Nov; 55(11):869. PubMed ID: 5687020
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed cutaneous hypersensitivity reactions to extracts of breast cancer and melanoma tissue in cancer patients.
    Fossati G; Canevari S; Pierotti MA; Vezzoni P; Porta GD; Vaglini M
    J Natl Cancer Inst; 1979 Jun; 62(6):1381-5. PubMed ID: 286110
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunologic responses in cancer patients.
    Solowey AC; Rapaport FT
    Surg Gynecol Obstet; 1965 Oct; 121(4):756-60. PubMed ID: 5838283
    [No Abstract]   [Full Text] [Related]  

  • 4. Isolation and identification of soluble skin-reactive membrane antigens of malignant and normal human breast cells.
    Hollinshead AC; Jaffurs WT; Alpert LK; Harris JE; Herberman RB
    Cancer Res; 1974 Nov; 34(11):2961-8. PubMed ID: 4138143
    [No Abstract]   [Full Text] [Related]  

  • 5. [Delayed hypersensitivity reactions in cancer patients: influence of the clinical stage and chemo- and radiotherapy on the immune status].
    Bouckenaere-Wojcik D; Delzenne G; Deckers C
    Bull Cancer; 1982; 69(5):468-75. PubMed ID: 7165809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No difference in delayed hypersensitivity between breast and cervical carcinomas.
    Munzarová M; Kovarík J; Ptácková B; Hlávková J; Kolcová V; Nebeský T
    Neoplasma; 1984; 31(1):95-8. PubMed ID: 6700799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte transformation in breast cancer.
    Roberts MM
    Br J Surg; 1970 May; 57(5):381. PubMed ID: 5427887
    [No Abstract]   [Full Text] [Related]  

  • 8. Why do some breast cancer cells remain dormant?
    Neves-E-Castro M
    Gynecol Endocrinol; 2006 Apr; 22(4):190-7. PubMed ID: 16723305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of cutaneous anergy for the surgical treatment of solid neoplasms.
    Morton DL; Eilber FR
    Natl Cancer Inst Monogr; 1971 Dec; 34():103-8. PubMed ID: 5140859
    [No Abstract]   [Full Text] [Related]  

  • 10. [Demonstration of breast neoplasm cells by means of the immunofluorescence technic].
    Fischer K; Poschmann A; Stegner HE
    Dtsch Med Wochenschr; 1977 Aug; 102(34):1227. PubMed ID: 334499
    [No Abstract]   [Full Text] [Related]  

  • 11. The presence of delayed hypersensitivity reactions in patients toward cellular extracts of their malignant tumors. 3. The frequency, duration, and cross reactivity of this phenomenon in patients with breast cancer, and its correlation with survival.
    Stewart TH; Orizaga M
    Cancer; 1971 Dec; 28(6):1472-8. PubMed ID: 5127795
    [No Abstract]   [Full Text] [Related]  

  • 12. Delayed cutaneous hypersensitivity reactions to extracts of malignant and normal breast cells.
    Alford C; Hollinshead AC; Heberman RB
    Ann Surg; 1973 Jul; 178(1):20-4. PubMed ID: 4717706
    [No Abstract]   [Full Text] [Related]  

  • 13. [CA 15.3 and early diagnosis of recurrence in breast cancer].
    Basuyau JP; Brunelle P; Charrot P; Chevallier B; Delapierre F; Graic Y; Julien JP; Veyret C
    Bull Cancer; 1993 Mar; 80(3):213-8. PubMed ID: 8173173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between delayed hypersensitivity responses and blood steroid and androgen levels in cancer patients.
    Mackay WD; Bulbrook RD; Want D
    Br J Surg; 1970 May; 57(5):386. PubMed ID: 5427901
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunological studies in breast cancer. Modifying activity of the serum (MSA).
    Cervantes C; Muzio E; Exposito G; Garcia ME
    Neoplasma; 1980; 27(4):379-86. PubMed ID: 7453855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolate local failure after breast-conserving treatment for early breast cancer, about 57 cases.
    Deniaud-Alexandre E; Lauratet B; Lefranc JP; Genestié C; Lerouge D; Moureau-Zabotto L; Touboul E
    Cancer Radiother; 2004 Apr; 8(2):95-107. PubMed ID: 15063877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Local recurrence and distant metastasis after breast-conserving therapy for patients with breast cancer].
    Meng J; Ning LS
    Zhonghua Wai Ke Za Zhi; 2003 Apr; 41(4):278-81. PubMed ID: 12882672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Peoples GE; Gurney JM; Hueman MT; Woll MM; Ryan GB; Storrer CE; Fisher C; Shriver CD; Ioannides CG; Ponniah S
    J Clin Oncol; 2005 Oct; 23(30):7536-45. PubMed ID: 16157940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune status in patients cured of breast and gynaecological cancer.
    Haim N; Rudik L; Samuelly B; Mekori T; Robinson E
    Clin Oncol; 1981 Jun; 7(2):141-7. PubMed ID: 7249436
    [No Abstract]   [Full Text] [Related]  

  • 20. [Cellular immunity indices in benign breast tumors].
    Baisheva SA; Zhalgasbaeva GT; Kaliev IuSh; Mezinova NN
    Vopr Onkol; 1980; 26(5):15-9. PubMed ID: 7385708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.